

With the endorsement of:



Grupo Español de Investigación en Cáncer de Ovario

2nd  
Multidisciplinary  
Meeting

**ONCO  
MING**

Let's step forward

# Program

Scientific Coordinator:

**Dr. Ana Oaknin**

(Hospital Universitario Vall d'Hebron, Barcelona)

MARCH 2022  
Aula del Mar  
Málaga (Spain)

DAY 1

## Friday, March 4th

### I Session: Advanced Ovarian Cancer: The evolving approach in first line therapy

Chair: **A. Oaknin**  
Hospital Universitario Vall d'Hebron, Barcelona

Co-Chair: **Isabelle Ray- Coquard**  
Centro Leon-Bernard, Lyon

- 17.00-17.05H** Welcome and introduction
- 17.05-17.25H** **Debulking Surgery (Initial/Interval) in times of PARPi: Less is More?**  
Anna Fagotti  
Policlinico Gemelli, Rome
- 17.25-17.45H** **Digging into molecular characterization of high-grade ovarian cancer: HRD and Beyond**  
Ana Vivancos  
Hospital Universitario Vall d'Hebron, Barcelona
- 17.45-18.05H** **Should we test all ovarian cancer patients for HRD status? When and How?**  
Ainhoa Madariaga  
Hospital Universitario 12 de Octubre, Madrid
- 18.05-18.25H** Discussion time
- 18.25-19.25H** **Time elapsed: Are currently PARPi widely used in first- line ovarian cancer therapy? Have we already known what is the most appropriate approach?**
  - 18.25-18.45H** **As monotherapy**  
Domenica Lorusso  
Policlinico Gemelli, Rome
  - 18.45-19.05H** **In combination with Bevacizumab**  
Isabelle Ray-Coquard  
Centro Leon-Bernard, Lyon
  - 19.05-19.25H** Discussion time

AstraZeneca   MSD

## Saturday, March 5th

### II Session:

#### The Good and the Bad of PARPi

Chair: **A. Oaknin**  
Hospital Universitario Vall d'Hebron, Barcelona

Co-Chair: **Domenica Lorusso**  
Policlinico Gemelli, Rome

**09.05-09.30H** **A decade of PARPi in Ovarian Cancer: What have we learnt?**  
**Jonathan Ledermann**  
University College London (UCL)

**09.30-10.10H** **What are the mechanisms of PARPi Resistance: Able to identify?**  
**09.30-09.50H** **In the Lab:**  
**Josep Forment**  
AstraZeneca Oncology R&D, Cambridge

**09.50-10.10H** **In the Clinic:**  
**Charlie Gourley**  
University of Edinburgh Cancer Research U.K Centre, Edinburgh

**10.10-10.30H** **Is there a Role for PARPi after PARPi? Lessons learnt from OReO Trial**  
**Alexandra Leary**  
Gustave Roussy Institute of Oncology, Paris

**10.30-11.00H** **Discussion time**

**11.00-11.30H** **Coffee-Break**

### III Session:

#### Exploiting the Replication Stress in Ovarian Cancer

Chair: **Ignacio Romero**  
Instituto Valenciano de Oncología, Valencia

Co-Chair: **Nicole Concin**  
Innsbruck Medical University, Innsbruck

**11.30-11.50H** **DNA damage response pathways: understanding its biologic transcendence**  
**Alan Lau**  
AstraZeneca Oncology R&D, Cambridge

**11.50-12.10H** **Exploiting the damage response in the clinic**  
**Susana Banerjee**  
Royal Marsden NHS Foundation Trust, London

**12.10-12.30H** **Discussion time**

### IV Session:

#### PARP inhibitors: do you want to dance with me?

Chair: **Antonio Casado**  
Hospital Clínico San Carlos, Madrid

Co-Chair: **M<sup>a</sup> Jesús Rubio**  
Hospital Universitario Reina Sofía, Córdoba

**12.30-12.50H** **First line therapy: the future of new combinations**  
**Nicoletta Colombo**  
Istituto Europeo di Oncologia, Milan

**12.50-13.10H** **Relapsed Ovarian Cancer: is there a future for them?**  
**Mansoor Mirza**  
Rigshospitalet, Copenhagen University Hospital

**13.10-13.30H** **Discussion time**

**13.30-13.45H** **Summary and close**